Covishield Controversy
The Covishield controversy centers around AstraZeneca’s recent admission in a UK court that its COVID-19 vaccine, developed with the University of Oxford and sold in India as Covishield, can cause Thrombosis with Thrombocytopenia Syndrome (TTS) in rare instances. This admission surfaced during a class-action lawsuit, where claimants are seeking damages for severe injuries and fatalities allegedly caused by the vaccine. Despite the rare risk of TTS, which manifests as blood clots accompanied by a low platelet count, health professionals emphasize the vaccine’s crucial role in preventing severe COVID-19, which itself can lead to similar health complications. The situation highlights the ongoing balance between vaccine efficacy and the management of potential side effects.
